Multiple myeloma experimental treatments are classified as myeloma treatments that are still under study. These experimental myeloma treatment options have not yet been approved by the FDA. However, they are intended to treat myeloma by improving on, supporting, or replacing conventional myeloma treatment methods. With a business model focused on accelerating cancer research, the MMRF has initiated more myeloma clinical trials, introduced more medicines, and had a greater impact than any other organization. The Multiple Myeloma Knowledge Center from the Multiple Myeloma Research Foundation provides detailed information on seven experimental myeloma treatments:
Aplidin is marine-derived antitumor agent being evaluated in combination with dexamethasone in a trial being conducted in the US & Europe. The drug has shown synergistic effects with other anti-myeloma drugs – it is given via intravenous infusion every 2 weeks.
Elotuzumab is a monoclonal antibody that is given as an intravenous infusion. Lab studies have shown that elotuzumab is capable of killing myeloma cells, including those that are resistant to other anti-myeloma therapies.
Ixazomib is a second-generation proteasome inhibitor. Proteasome inhibitors work by blocking enzymes from multiple myeloma cells, hindering their ability to grow and survive. Ixazomib is administered orally and initially studies have proven the drug is more effective than Velcade, a first-generation proteasome inhibitor.
Marizomib is another proteasome inhibitor that blocks the activity of proteasomes. By blocking the proteasome, Marizomib disrupts processes related to the growth and survival of myeloma cells. The drug is given as an intravenous infusion, and it is currently being evaluated in patients with relapsed or refractory myeloma.
Treanda is a chemotherapy treatment that is administered intravenously. Treanda is currently understood to kill tumor cells by damaging their DNA. The drug has been approved for myeloma in treatment in Germany, and the FDA has approved it for use in the treatment of leukemia as well as lymphoma.
Zolinza is a histone deacetylase inhibitor that has been shown to inhibit cancer cell growth and to induce myeloma cell death. The drug is administered orally and is currently FDA-approved for use in treating lymphoma. Common Zolinza side effects seen in studies included low blood cell and platelet counts, diarrhea, and fatigue.
For more information on multiple myeloma experimental treatments, contact a physician.